Latest filing published 18 Dec 2024 for Catalent, Inc.. Read the official filing
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Lisa Evoli (senior executive) discloses dealings in 2 companies, chiefly Integra Lifesciences Holdings Corp and Catalent, Inc. We count 17 filings; the first trade dates from 1 February 2016 and the latest from 18 December 2024.
The open-market record consists of 6 sales worth €617k, with no purchase. Outside the open market, there are 9 share grants and 1 option exercise. In 2024 alone, the filings show no purchases and 1 sale.
Most recently, on 18 December 2024, the filings show a transaction in Catalent, Inc. The median gap between a trade and its publication by SEC (Form 4) is 2 days. The legal deadline for a Form 4 is two business days after the transaction. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
17 of 17 declarations